Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA
You may also be interested in...
Korea’s Dong-A Wins WHO Prequalification For TB Generic Of Lilly’s Seromycin As Firm Moves Up Value Chain
WHO prequalification clears path for Korea’s Dong-A to move from an API supplier of cycloserine to an exporter of finished products.
Korean Pharma Earnings Roundup: Dong-A, Green Cross Retain Leading Positions While Yuhan, LG Life, Hanmi Struggle
SEOUL - Of South Korea's five top pharmaceutical companies, Dong-A and Green Cross did relatively well in 2010, retaining their leading positions while Yuhan, LG Life Sciences and Hanmi failed to witness upward momentum amid a tightened government grip on the local pharmaceutical industry
Korea’s Bukwang To Sell Hepatitis B Drug In Philippines, Plans Launches In U.S., Europe
SEOUL - South Korea's Bukwang Pharmaceutical will begin selling its chronic hepatitis B drug Levovir (clevudine) in the Philippines in June, and plans to eventually launch the product across Asia, the U.S. and Europe, according to a company executive